Lupus (SLE): open trials in China

67 open trials have a site in China. Registry data; only the trial team decides who can take part.

NCT07629583
To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
Trial Treatment · Phase 1 · Genentech, Inc.
Peking University People's Hospital, Beijing · Peking University First Hospital, Beijing · Pingxiang People's Hospital, Pingxiang
Registry updated 2026-11-05
NCT07901764
MYTP01 for Immune-Mediated Diseases
Trial Treatment · Zhejiang Provincial People's Hospital
Zhejiang Provincial People's Hospital, Hangzhou
Registry updated 2026-11-04
NCT07201558
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
Trial Treatment · Phase 1 · AstraZeneca
Beijing · Chengdu · Nanjing
Registry updated 2026-10-28
NCT07104721
A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
Trial Treatment · Phase 1 · China Immunotech (Beijing) Biotechnology Co., Ltd.
The First Affiliated Hospital of Anhui Medical University, Hefei
Registry updated 2026-10-21
NCT07123519
A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
Trial Treatment · Phase 1 · China Immunotech (Beijing) Biotechnology Co., Ltd.
Institute of Hematology & Blood Diseases Hospital, China, Tianjin
Registry updated 2026-10-21
NCT06711887
Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
Trial Treatment · Phase 3 · Novartis Pharmaceuticals
Beijing · Binzhou · Changchun · Chongqing · Guangzhou · Liuzhou · Ningbo · Shanghai · Shantou · Shenyang · Shenzhen · Wuhan
Registry updated 2026-10-13
NCT03001973
High Quality Evidence of Chinese Lupus Nephritis (HELP)
Research · Sun Yat-sen University
The First Affiliated Hospital, Sun Yat-sen University, Guangzhou
Registry updated 2026-09-15
NCT06314282
INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World Use
Research · AstraZeneca
Guangzhou · Hong Kong · Shenzhen · Zhongshan · Zhuhai
Registry updated 2026-09-01
NCT07767188
A Trial to Explore the Efficacy and Safety of O-triple as Initial Therapy in the Active Lupus Nephritis Patients (INITIAL Trial)
Trial Treatment · Phase 3 · Zhao Minghui
Peking University First Hospital, Beijing · Fujian Medical University Union Hospital, Fuzhou · Guangdong Provincial People's Hospital, Guangzhou · Zhujiang Hospital of Southern Medical University, Guangzhou · The First Affiliated Hospital of Harbin Medical University, Harbin · The Affiliated Hospital of Southwest Medical University, Luzhou · The First Affiliated Hospital of NanChang University, Nanchang · Jiangsu Province Hospital, Nanjing · Shengjing Hospital affiliated to China Medical University, Shenyang · Tianjin Medical University General Hospita, Tianjin · The First Affiliated Hospital of Xinjiang Medical University, Ürümqi · The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an · The affiliated hospital of xuzhou medical university, Xuzhou · Yantai Yuhuangding Hospital, Yantai
Registry updated 2026-08-26
NCT06711146
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Moderate to Severe Active SLE Clinical Research
Trial Treatment · Early phase 1 · Zhejiang University
The first affiliated hospital of medical college of zhejiang university, Hangzhou
Registry updated 2026-08-24
NCT06801119
Efficacy and Safety of HN2301 in Autoimmune Diseases（AIDs）
Trial Treatment · Phase 1 · Shenzhen MagicRNA Biotechnology Co., Ltd
The First Affiliated Hospital of University of Science and Technology of China, Hefei
Registry updated 2026-08-12
NCT07483346
IASO-782 in Systemic Lupus Erythematosus
Trial Treatment · Phase 1 · Shanghai IASO Biotechnology Co., Ltd
Affiliated Hangzhou First People's Hospital, Westlake University School of Medicine, Hangzhou · The First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou · Huzhou Central Hospital, Huzhou · The First Hospital Of Jiaxing, Jiaxing
Registry updated 2026-08-10
NCT06947460
CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH
Trial Treatment · Phase 1/2 · Beijing GoBroad Hospital
Beijing
Registry updated 2026-07-30
NCT07719140
Childhood-onset Lupus Nephritis Initial Glucocorticoid-dose Harmonization Trial (LIGHT Trial)
Trial Treatment · Phase 4 · Peking Union Medical College Hospital
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing · Beijing Children's Hospital, Capital Medical University, Beijing · Jilin University, Changchun · The Second Xiangya Hospital of Central South University, Changsha · Chidren's Hospital of Chongqing Medical University, Chongqing · Children's Hospital of Nanjing Medical University, Nanjing · Children's Hospital Of Fudan University, Shanghai · Shenzhen Children's Hospital, Shenzhen
Registry updated 2026-07-22
NCT07596680
CD19/BCMA-Targeted Universal CAR-T Cell Injection for the Treatment of Autoimmune Diseases
Trial Treatment · Early phase 1 · Nanjing Bioheng Biotech Co., Ltd.
Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai
Registry updated 2026-07-16
NCT07706998
Application of the AI Platform iLN Based on DeepSeek in the Teaching of Lupus Nephritis
Trial Treatment · Nanjing University
Nanjing University, Nanjing
Registry updated 2026-07-16
NCT06285279
The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases
Trial Treatment · Phase 1 · Nanjing University School of Medicine
Jinling Hospital, Nanjing
Registry updated 2026-07-06
NCT07674147
RD06-05 Universal CD19/BCMA CAR-T for Refractory Pediatric Autoimmune Diseases
Trial Treatment · Early phase 1 · The Children's Hospital of Zhejiang University School of Medicine
Children's Hospital, Zhejiang University School of Medicine, Hangzhou · Nanjing Children's Hospital, Nanjing
Registry updated 2026-06-29
NCT07517536
CHT105 for the Treatment of Refractory Lupus Nephritis
Trial Treatment · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing
Registry updated 2026-06-18
NCT06676631
NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis
Trial Treatment · Phase 1 · Guangdong Provincial People's Hospital
Guangdong Provincial People's Hospital, Guangzhou
Registry updated 2026-06-12
NCT07629596
Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of Arnovie101, an mRNA-LNP-Based In Vivo CAR-T Therapy, for the Treatment of B Cell-Mediated Autoimmune Diseases (SLE and AIHA)
Trial Treatment · Early phase 1 · Circunited BioPharma (Shenzhen) Co., Ltd.
Beijing Gobroad Boren Hospital, Beijing
Registry updated 2026-06-05
NCT07593911
A Study to Evaluate MTM-H-001 Injection in Adult Patients With B-Cell-Related Autoimmune Diseases
Trial Treatment · Beijing GoBroad Hospital
Beijing GoBroad Hospital, Beijing
Registry updated 2026-05-18
NCT07535138
Efficacy and Safety of CD19 CAR-γδ T Cells in the Treatment of Relapsed/Refractory Autoimmune Nephropathy
Trial Treatment · Early phase 1 · Air Force Military Medical University, China
Xijing hospital, Xi'an
Registry updated 2026-04-16
NCT07193810
A Study of CC312 for Relapsed/Refractory Autoimmune Diseases
Trial Treatment · Early phase 1 · CytoCares Inc
Deyang People's Hospital, Deyang
Registry updated 2026-04-14
NCT07523542
SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus
Trial Treatment · Phase 1/2 · Beijing Biotech
Peking University Shenzhen Hospital, Shenzhen
Registry updated 2026-04-13

All Lupus (SLE) trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error